Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

PHASE2TerminatedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

May 15, 2022

Primary Completion Date

September 26, 2024

Study Completion Date

January 30, 2025

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

PTC857

PTC8657 will be administered as an oral solution twice a day.

DRUG

Placebo

Matching placebo will be administered as an oral solution twice a day.

Trial Locations (55)

3000

UZ Leuven, Leuven

3084

Austin Health, Heidelberg

3162

Calvary Health Care Bethlehem, Caulfield South

4029

Royal Brisbane and Women's Hospital, Brisbane

4215

Gold Coast Hospital, Southport

7747

University Hospital Jena, Jena

9000

AZ Sint-Lucas Gent, Ghent

10126

AOU Citta Della Salute e Scienza, Torino

13353

Charite - Universitatsmedizin - Berlin, Berlin

19140

Lewis Katz School of Medicine at Temple Universtiy, Philadelphia

20138

Istituti Clinici Scientifici Maugeri IRCCS, Milan

20149

Istituto Auxolgoico Italiano, Milan

23538

Universitaetsklinikum Schleswig-Holstein (UKSH) Campus Luebeck, Klinik fuer Neurologie, Praezisionsneurologie, Lübeck

25123

Centro Clinico Nemo Brescia, Brescia

27100

IRCCS Fondazione Mondino - Reparto Neuroncologia/Neuroinfiammazione, Pavia

28100

Maggiore della Carita University Hospital, Neurology department, ALS center, Novara

30625

Hannover Medical School, Hanover

30912

Augusta University, Augusta

33076

CHU de Bordeaux, Bordeaux

33308

Holy Cross Hospital, Phil Smith Neuroscience Institute, Fort Lauderdale

33612

University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare, Tampa

34295

CHU Gui de Chauliac (Pharmacie Saint-Eloi & Gui de Chauliac, Hopital Saint-Eloi), Montpellier

41126

Azienda Ospedaliero Universitaria di Modena, Modena

46026

Hospital Universitario y Politecnico La Fe, Valencia

48202

Henry Ford Health System Department of Neurology, Detroit

53226

Medical College of Wisconsin, Milwaukee

59037

CHRU Lille - Hôpital Roger Salengro, Lille

62500

University hospital Brno, Department of Neurology, Brno

63000

CHU Gabriel Montpied, Clermont-Ferrand

66205

University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City

68506

Neurology Associates, P.C. / Somnos Clinical Research, Lincoln

69677

Hôpital Neurologique Pierre Wertheimer, Bron

77030

Nerve and Muscle Center of Texas, Houston

78759

National Neuromuscular Research Institute, Austin

87000

CHU Dupuytren 1 Limoges, Limoges

89081

University of Ulm, Dept. of Neurology, Ulm

90127

"ALS Clinical Research Center, University Hospital Policlinico P Giaccone", Palermo

90185

Norrlands universitetssjukhus Neurologens Forskningsavdelning, Umeå

92868

UC Irvine Health ALS and Neuromuscular Center, Orange

94109

Forbes Norris MDA/ALS Research Center at California Pacific Medical Center, San Francisco

97213

Providence Brain and Spine Institute, Portland

68198-8440

University of Nebraska Medical Center, Omaha

C1023AAB

STAT Research S.A., Ciudad Autónoma de Buenos Aires

C1015ABR

Iadin Srl., Buenos Aires

CP 1221

Hospital Ramos Mejía, Buenos Aires

160 00

FORBELI s.r.o., Prague

06200

CRMR SLA - MNM du CHU de Nice, Nice

00161

Policlinico Umberto I, Roma

Unknown

PTC Clinical Site, Japanese City

3584 CW

UMC Utrecht, Utrecht

01-684

Centrum Medyczne Neuro Protect, Warsaw

02-473

City Clinic Research Sp. Z o.o, Warsaw

08035

Unidad Neuromuscular. Servicio de Neurologia Hospital Universitari Vall d'Hebron, Barcelona

08041

H. St Pau, Barcelona

SE-211 24

Skanes universitetssjukhus, VE Neurologi, Malmo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT05349721 - Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | Biotech Hunter | Biotech Hunter